BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, September 25, 2023
Home » Topics » Conferences, BioWorld Asia

Conferences, BioWorld Asia
Conferences, BioWorld Asia RSS Feed RSS

Conference data for Sept. 19, 2023: IASLC-WCLC

Sep. 19, 2023
No Comments
New and updated clinical data presented by biopharma firms at the International Association for the Study of Lung Cancer, 2023 World Conference on Lung Cancer, including: Astrazeneca, Daiichi.
Read More
Park Eun-young, CEO Ainb

GBC 2023: In generative AI era, collaboration key for drug discovery

Sep. 5, 2023
By Marian (YoonJee) Chu
No Comments
Rapidly evolving artificial intelligence (AI) is effectively resetting all biopharmaceutical companies to the figurative starting line, and collaboration is a key strategy to winning the drug discovery race, an AI-based startup founder said at the Global Bio Conference (GBC) 2023.
Read More

IAS 2023: Will long-acting treatments be the next game changer for people living with HIV?

Aug. 8, 2023
By Tamra Sami
No Comments
For people living with HIV, the single greatest achievement to date has been the emergence of antiretroviral treatments (ART) that completely block the virus, resulting in reduced mortality and morbidity and improved quality of life. But taking one pill a day for life cannot be the end of this journey, speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia.
Read More
HIV infected cell

IAS 2023: Broadly neutralizing antibodies bring potential cure for HIV closer (part 2)

Aug. 1, 2023
By Tamra Sami
No Comments
Broadly neutralizing antibodies (bNAbs) have the potential to prevent HIV, and more researchers are turning to bNAbs as an alternative to antiretroviral therapy (ART), speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia. However, for a cure, the viral reservoir that is formed in the early stages of HIV remains an obstacle, and recent studies suggest that controlling or eliminating the HIV reservoir with bNAbs might be possible.
Read More
HIV-1 virus particle
HIV/AIDS

IAS 2023: Vaccines and broadly neutralizing antibodies bring cure for HIV one step closer

Aug. 1, 2023
By Tamra Sami
No Comments
Although huge strides have been made with antiretroviral therapy (ART) and prevention since HIV was first reported 42 years ago, there is still not an effective preventive vaccine or a scalable cure for those living with HIV. But broadly neutralizing antibodies (bNAbs) look to be a further step down the pathway to a cure, speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia.
Read More
HIV-1 virus particle

IAS 2023: Sydney close to eradicating HIV but experts warn the last mile is the hardest

July 25, 2023
By Tamra Sami
No Comments
The HIV journey is a roller coaster of highs and lows for the patients living with HIV and their families and loved ones but also for the community of researchers and clinicians who pour their hearts and souls into the work they do, said speakers at the International AIDS Society (IAS) 2023 conference in Brisbane, Australia.
Read More

Conference data for July 25, 2023: AAIC

July 25, 2023
No Comments
New and updated clinical data presented by biopharma firms at the Alzheimer's Association International Conference, including: Nkgen.
Read More
BIX Korea panel

BIX Korea: Leqembi may be overpriced, but it’s worth the fight, experts say

July 18, 2023
By Marian (YoonJee) Chu
No Comments
Questionable efficacy, high priced and risky side effects are some words to describe Leqembi (lecanemab), the latest amyloid beta-targeting antibody approved by the U.S. FDA, Korean experts said, but none of that diminishes the profound significance of the drug for Alzheimer’s disease.
Read More

Conference data for July 11, 2023: EASL

July 11, 2023
No Comments
New and updated clinical data presented by biopharma firms at the European Association for the Study of the Liver Congress, including: Arrowhead, Takeda.
Read More

Curocell reports positive interim phase II results on Korean CAR T therapy, aims for NDA in 2024

June 20, 2023
By Marian (YoonJee) Chu
No Comments
Curocell Inc. is inching closer to realizing Korea’s first domestically developed CAR T therapy, presenting “encouraging” interim phase II trial results for anbalcabtagene-autoleucel at the International Conference on Malignant Lymphoma in Lugano, Switzerland.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 16 17 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing